Incidence and risk factors for chronic rejection in pediatric liver transplantation

医学 肝移植 入射(几何) 风险因素 重症监护医学 梅德林 移植 内科学 物理 光学 政治学 法学
作者
Peace N. Dike,Deborah Schady,Ryan Himes,John A. Goss,Danielle Guffey,Dana Cerminara,Krupa R. Mysore
出处
期刊:Liver Transplantation [Wiley]
标识
DOI:10.1097/lvt.0000000000000488
摘要

Chronic rejection (CR) is a progressive immunological injury that frequently leads to long-term liver allograft dysfunction and loss. Although CR remains an important indication for re-transplantation, as transplant immunosuppression has evolved, its prevalence in adults undergoing liver transplantation (LT) has declined. However, the incidence and factors that lead to CR in pediatric LT are poorly defined. Therefore, we sought to systematically measure CR's incidence and assess both the risk factors for developing CR and outcomes in a large cohort of pediatric LT recipients. In this single center study, we retrospectively analyzed and compared relevant recipient characteristics, surgical details, immunosuppression, graft, and patient survival in the CR and control groups over a 17-year period. After a median time of 1.9 years post-LT, 19/356 LT recipients (5.3%) developed CR in our cohort. Post-transplant lymphoproliferative disorder (p=0.01), infections (p=0.02), autoimmune liver diseases (HR 7.3, p=<0.01), Black race (HR11.5, p=0.01) and two or more episodes of acute cellular rejection (HR 5.1, p=<0.01) were associated with CR development. The re-transplantation rate among CR cases was 15.8% at a median follow-up time of 4.1 years. Overall, patient survival was lower in the CR group (78.9%) versus controls (91.1%). While CR incidence in our pediatric cohort was lower than previously reported rates of ˃12%, the CR group had a higher graft failure rate that required re-transplantation and lower overall patient survival. Thus, identifying risk factors may warrant specialized immunosuppression protocols and closer post-transplantation monitoring to reduce the risk of morbidity and mortality from CR.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
叶未晞yi发布了新的文献求助10
刚刚
ipeakkka发布了新的文献求助10
1秒前
Jzhang应助迷人的映雁采纳,获得10
1秒前
1秒前
zzz完成签到,获得积分10
2秒前
2秒前
小安发布了新的文献求助10
2秒前
3秒前
叶未晞yi完成签到,获得积分10
5秒前
科研通AI5应助科研通管家采纳,获得10
5秒前
传奇3应助科研通管家采纳,获得10
5秒前
Akim应助科研通管家采纳,获得30
5秒前
科研通AI5应助科研通管家采纳,获得10
6秒前
kilig应助科研通管家采纳,获得10
6秒前
6秒前
华仔应助科研通管家采纳,获得30
6秒前
6秒前
科研通AI5应助科研通管家采纳,获得10
6秒前
博ge发布了新的文献求助10
8秒前
9秒前
葶儿发布了新的文献求助10
9秒前
hgcyp完成签到,获得积分10
14秒前
ysh完成签到,获得积分10
14秒前
14秒前
16秒前
16秒前
17秒前
wang完成签到,获得积分10
18秒前
Jzhang应助Yimim采纳,获得10
19秒前
沐风发布了新的文献求助20
20秒前
汉关发布了新的文献求助10
22秒前
22秒前
葶儿完成签到,获得积分10
22秒前
安详中蓝完成签到 ,获得积分10
23秒前
呆萌士晋发布了新的文献求助10
23秒前
23秒前
25秒前
呆头发布了新的文献求助10
27秒前
若水发布了新的文献求助200
28秒前
28秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
Luis Lacasa - Sobre esto y aquello 700
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527990
求助须知:如何正确求助?哪些是违规求助? 3108173
关于积分的说明 9287913
捐赠科研通 2805882
什么是DOI,文献DOI怎么找? 1540119
邀请新用户注册赠送积分活动 716941
科研通“疑难数据库(出版商)”最低求助积分说明 709824